REGN - Regeneron Pharmaceuticals, Inc.
After hours:
| Previous close | 731.17 |
| Open | 730.31 |
| Bid | 729.73 x 800 |
| Ask | 743.00 x 1000 |
| Day's range | 724.12 - 740.16 |
| 52-week range | 538.01 - 837.55 |
| Volume | |
| Avg. volume | 578,634 |
| Market cap | 81.18B |
| Beta (5Y monthly) | 0.22 |
| PE ratio (TTM) | 20.00 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study
A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.
- Simply Wall St.
Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their solid 158% return over the last five years
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...
- Zacks
Regeneron (REGN) Faces Challenges as Eylea Sales Decline
Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.
- Simply Wall St.
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Regeneron Pharmaceuticals (NASDAQ:REGN) has had a rough month with its share price down 9.4%. However, stock prices are...
- Motley Fool
2 Cathie Wood Stocks That Can Get You Through Any Recession
Economists at the U.S. Federal Reserve recently uttered the dreaded "R" word. They are now predicting a recession will come later this year. Investors have been bracing for this possibility for a while now, so it shouldn't come as too much of a surprise.
- Simply Wall St.
Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 29% Discount?
Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,053 based on 2 Stage Free Cash Flow to...
- Simply Wall St.
Regeneron Pharmaceuticals Insider Lowered Holding By 26% During Last Year \
From what we can see, insiders were net sellers in Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) during the past 12...
- Motley Fool
Why Regeneron Pharmaceuticals Stock Is Tanking Today
Regeneron Pharmaceuticals (NASDAQ: REGN), a large-cap biotechnology company, is under heavy pressure today. Specifically, the biotech's stock was down by an unsightly 6.5% on heavy volume as of 12:19 p.m. ET Thursday afternoon. Regeneron's shares are moving southward in response to lower-than-expected sales of its flagship eye-care treatment, Eylea, during the first quarter of 2023.
- Zacks
Regeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline
Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.
- Zacks
Here's What Key Metrics Tell Us About Regeneron (REGN) Q1 Earnings
While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- Zacks
Regeneron (REGN) Q1 Earnings and Revenues Top Estimates
Regeneron (REGN) delivered earnings and revenue surprises of 9.08% and 8.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Drug, Biotech Stocks' Q1 Earnings on May 4: REGN, ZTS & More
Let us look at four big drug and biotech companies, REGN, ZTS, MRNA and NVO, which are gearing up for their earnings release.
- Zacks
Why Earnings Season Could Be Great for Regeneron (REGN)
Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Zacks
LGND vs. REGN: Which Stock Is the Better Value Option?
LGND vs. REGN: Which Stock Is the Better Value Option?
- Zacks
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
- Zacks
Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?
Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.
- Zacks
Regeneron (REGN) Gains But Lags Market: What You Should Know
In the latest trading session, Regeneron (REGN) closed at $792.29, marking a +1.84% move from the previous day.
- Zacks
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates
We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.
- Simply Wall St.
Does Regeneron Pharmaceuticals (NASDAQ:REGN) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- Zacks
Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Regeneron (REGN) closed at $800.73, marking a +0.33% move from the previous day.
- Zacks
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
- Simply Wall St.
Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their splendid 159% return over the last five years
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if...
- Simply Wall St.
Are Strong Financial Prospects The Force That Is Driving The Momentum In Regeneron Pharmaceuticals, Inc.'s NASDAQ:REGN) Stock?
Regeneron Pharmaceuticals (NASDAQ:REGN) has had a great run on the share market with its stock up by a significant 15...
- Motley Fool
Investing $1,000 In These 2 Top Stocks Would Be a Great Move
For those with $1,000 that isn't being saved for emergencies, here are two excellent stocks to buy today: HCA Healthcare (NYSE: HCA) and Regeneron (NASDAQ: REGN). HCA Healthcare is a leading hospital chain in the U.S. It makes money based on occupancy rates in its 182 hospitals (among other facilities) and based on the services physicians order for their patients. For instance, occupancy levels in HCA Healthcare's hospitals would soar along with the number of cases of COVID-19 and then drop back down, sometimes rendering year-over-year comparisons difficult.
